ResMed, a global leader in digital health and cloud-connected medical devices, announced on July 10, 2026, that it has entered into a definitive agreement to sell its MatrixCare software business to private equity firm Francisco Partners. The transaction, valued at approximately $817 million in cash, marks a strategic shift for the San Diego-based company as it moves to streamline its portfolio and sharpen its focus on core respiratory and sleep care technologies.
According to the official ResMed investor relations disclosure, the divestiture of MatrixCare—a provider of software-as-a-service (SaaS) solutions for the out-of-hospital care sector—is expected to close by the end of the 2026 calendar year, subject to customary closing conditions and regulatory approvals. For the thousands of healthcare providers currently utilizing MatrixCare for electronic health records and billing, the transition signals a change in ownership rather than an immediate disruption to service.
Strategic Rationale for the Divestiture
ResMed’s decision to offload MatrixCare follows a period of portfolio evaluation aimed at prioritizing high-growth areas within its core business. ResMed originally acquired MatrixCare in 2018 for $750 million, seeking to expand its footprint in the post-acute care market, including skilled nursing, life plan communities, and home health agencies. By selling the asset to Francisco Partners, ResMed is effectively exiting the long-term post-acute care (LTPAC) software space to reinvest capital into its cloud-based medical device ecosystem.
The financial terms of the deal reflect a modest valuation gain over the original purchase price, accounting for the growth of the business under ResMed’s stewardship. Francisco Partners, which specializes in investments within the technology and healthcare IT sectors, has stated its intent to support MatrixCare’s continued expansion. The divestment is part of a broader trend where medical device manufacturers are increasingly decoupling from diversified software holdings to focus on vertically integrated product lines, according to industry analysis provided by Reuters.
Impact on Healthcare Providers and Operations
The primary concern for current MatrixCare users remains the continuity of their clinical and administrative platforms. In its statement, ResMed emphasized that the transition will be managed to ensure minimal operational friction. Because MatrixCare operates as a SaaS platform, the underlying infrastructure relies on cloud-based data management, which requires seamless migration of service contracts and technical support teams under the new ownership.
Institutional clients, including nursing homes and home health providers, should monitor the official MatrixCare portal for updates regarding technical support and account management. Regulatory filings indicate that the transition will involve the transfer of personnel and intellectual property associated with the MatrixCare division to the new owners. The sale does not affect ResMed’s primary products, such as continuous positive airway pressure (CPAP) machines or its Brightree software business, which remains a separate entity in the company’s portfolio.
Francisco Partners’ Role in Healthcare IT
Francisco Partners’ acquisition of MatrixCare aligns with its history of acquiring and scaling healthcare technology assets. The firm has previously invested in companies focused on health information exchange and clinical workflow automation. By acquiring a mature platform with an established client base in the skilled nursing and home health industries, Francisco Partners aims to leverage MatrixCare’s existing market position to drive further innovation in post-acute care.
Analysts note that this transaction is likely to be viewed as a “clean break” for ResMed, allowing the company to reduce the complexity of its balance sheet while freeing up resources for research and development in its core sleep apnea and COPD treatment sectors. As noted in recent financial reporting, the shift allows ResMed to better compete with specialized medical technology firms by narrowing its operational focus.
Next Steps in the Transaction Process
The completion of the sale is contingent upon the satisfaction of standard regulatory requirements, including antitrust reviews common in large-scale technology acquisitions. Both ResMed and Francisco Partners have indicated that they are working toward a transition date scheduled for the fourth quarter of 2026.
Stakeholders, including shareholders and institutional healthcare partners, should look for further updates in ResMed’s upcoming quarterly earnings reports. The company has committed to providing guidance on how the proceeds from the $817 million sale will be allocated, whether through debt reduction, share repurchases, or future strategic investments. Please share your thoughts or questions in the comments section below regarding how this shift in the healthcare software market may affect your organization.